CyFlow CD264 Azide Free
品番 | CH296525 | ||
---|---|---|---|
抗体名 | Anti-Hu CD264 AZIDFREE,TRAILR401 | ||
包装単位 | 0.1 mg | ||
濃度 | 1 mg/ml | ||
容量 | 0.1 ml | ||
関連製品 (アイソタイプコントロール) |
- | ||
反応性|交差吸着 | Human | レーザー | |
抗原 | CD264, TRAIL-R4, DCR2 | 最大蛍光波長 | - |
クローン | TRAIL-R4-01 | 最大励起波長 | - |
ホスト | Mouse | 標識/Format | Azide Free |
アイソタイプ | IgG1 | 研究分野 | Immunophenotyping | Apoptosis |
クローナリティ | monoclonal | 用途 | Flow cytometry |
Anti-Hu CD264 AZIDFREE,TRAILR401
特異性
The mouse monoclonal antibody TRAIL-R4-01 recognizes CD264 (TRAIL-R4) antigen, a 42 kDa transmembrane protein expressed on various blood cells.
抗原情報
CD264 (TRAIL-R4, TR4, DcR2, TRUNDD), expressed mainly on CD8+ and NK cells, belongs to receptors of TRAIL, a TNF-like membrane toxic protein that induces apoptosis in many tumor cells, but not in normal cells. TRAIL-R4, however, contains partially truncated death domain, thus it is unable to induce apoptosis and serves as a negative regulator of apoptotic signaling by impairment death-inducing signaling complex (DISC) processing. TRAIL-R4 interacts with death receptor 5 (DR5) in the native DISC in a TRAIL-dependent manner and prevents its corecruitment with death receptor 4 (DR4).
利用方法
保存方法
Avoid prolonged exposure to light. Store in the dark at 2-8°C. Do not freeze.
安定性情報
Do not use after expiration date stamped on vial label.
レファレンス
• Clancy L, Mruk K, Archer K, Woelfel M, Mongkolsapaya J, Screaton G, Lenardo MJ, Chan FK: Preligand assembly domain‑mediated ligand‑independent association between TRAIL receptor 4 (TR4) and TR2 regulates TRAIL‑induced apoptosis. Proc·Natl·Acad·Sci·USA. 2005·Dec·13; 102(50):18099‑104. <·PMID:·16319225·>
• Deligezer U, Dalay N: Expression of the TRAIL Receptors in Blood Mononuclear Cells in Leukemia. Pathol·Oncol·Res. 2007; 13(4):290‑4. <·PMID:·18158563·>
• Falschlehner C, Emmerich CH, Gerlach B, Walczak H: TRAIL signalling. Int·J·Biochem·Cell·Biol. 2007; 39(7‑8):1462‑75. <·PMID:·17403612·>
• Mérino D, Lalaoui N, Morizot A, Schneider P, Solary E, Micheau O: Differential inhibition of TRAIL‑mediated DR5‑DISC formation by decoy receptors 1 and 2. Mol·Cell·Biol. 2006·Oct; 26(19):7046‑55. <·PMID:·16980609·>
• Sanlioglu AD, Dirice E, Aydin C, Erin N, Koksoy S, Sanlioglu S: Surface TRAIL decoy receptor‑4 expression is correlated with TRAIL resistance in MCF7 breast cancer cells. BMC·Cancer. 2005·May·25; 5(1):54. <·PMID:·18518976·>
Available Safety Data Sheets
CyFlow™ monoclonal antibodies SDS CA EN